
Opinion|Videos|February 10, 2025
Real World Perspectives: Considerations and Challenges for CAR T-cell Therapy in Relapsed/Refractory DLBCL
An overview of challenges with CAR T-cell therapy, including combating T-cell exhaustion, the pros and cons of outpatient administration, logistical barriers, and the role of polatuzumab in bridging therapy, along with a discussion of non-cellular second-line options such as pola+BR and findings from L-MIND compared to real-world data
Advertisement
Video content above is prompted by the following:
Please give an overview of outstanding challenges for both patients and practitioners with the CAR T-cell regimen.
- How can T-cell exhaustion be combated?
- What are the advantages and limitations of outpatient administration. In your opinion, how can any issues with outpatient administration be addressed?
- What other logistical barriers are present with CAR T-cell regimens, and how does bridging therapy help address these concerns?
- What are your thoughts on the use of polatuzumab (pola) in bridging therapy (
Liebers et al. Blood Adv 2021 ;Kim et al. ASH 2024 )?
For a patient who does not receive 2L cellular therapy whether based on logistical or clinical reasons, what are the available treatment options?
- Please discuss key takeaways from pola+ BR (
Sehn et al. Blood Adv. 2022 ). What can we learn from these updates? - What are the major findings from L-MIND, and how does that compare to real world data (
Duell J et al. Haematologica 2021 ;Zinzani et al. Clin Cancer Res 2021 )? - In your practice, how would you choose between the available options?
Advertisement
Related to this article

Pertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.

The European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.

Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.

The Pan-Mass Challenge donated a record $80 million to Dana-Farber Cancer Institute to support cancer research, treatment, and patient care.

Onvansertib plus FOLFIRI/bevacizumab earned fast track status in first-line KRAS- or NRAS-mutated metastatic colorectal cancer.

The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer
2
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
3
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
4
Cretostimogene Grenadenorepvec Improves RFS in Intermediate-Risk and High-Grade Ta NMIBC
5

